ClinicalTrials.gg
Status unknownNCT04556071AVANIRA3Updated Nov 10, 2020

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

A Phase 2 interventional study of Niraparib and Bevacizumab in Ovarian Neoplasms, Fallopian Tube Neoplasms and Endocrine Gland Neoplasms, sponsored by Xiaoxiang Chen. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-10.

Primary conditionCarcinoma, Ovarian EpithelialRegistry: Ovarian NeoplasmsReclassifiedWhy we changed it
Registry
Ovarian Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Ovarian Epithelial
Why
  1. The study's listed conditions name Carcinoma, Ovarian Epithelial, a narrower term within Ovarian Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Xiaoxiang Chen · Phase 2, Interventional, and Treatment

How we know · 5 judgments

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial — 1 open to participants now, 2 under way, none of them phase 3. Bevacizumab · Carcinoma, Ovarian Epithelial.

Planned enrollment
12th of 17
32 · median 40
Started
2020
the only one that year
Phase 2
11 of 17
none open now
Registered
14th of 17
by date

Among the 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial, this one is the 12th largest by planned enrollment, is the only one that started in 2020, is one of 11 in phase 2, and was the 14th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 101 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

1 of the 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 49 (65%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing bevacizumab in Carcinoma, Ovarian Epithelial, or all of them as a file.
02

Study summary

Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits tumor angiogenesis and is also recommended for the treatment of recurrent ovarian cancer. Clinical studies showed that niraparib combined with bevacizumab could significantly prolong progression free survival of platinum sensitive recurrent ovarian cancer. We intend to conduct a single-arm, prospective, open-label, phase II study to observe the efficacy and safety of niraparib combined with bevacizumab in the treatment of FIGO III/IV platinum refractory/resistant ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The results are expected to provide more effective and precise treatment for platinum resistant recurrent/refractory ovarian cancer patients.

Read the detailed description

The study is a single-arm, prospective, open-label, phase II study to observe the efficacy and safety of niraparib combined with bevacizumab in the treatment of FIGO III/IV platinum refractory/resistant ovarian cancer, fallopian tube cancer and primary peritoneal cancer.The primary end point is the objective response rate, and the secondary end points are progression free survival, duration of remission, disease control rate and safety. We also stratified analysis the level of tumor load, the status of BRCA and HRD on the efficacy and safety.

03

Conditions studied

  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Endocrine Gland Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Genital Neoplasms, Female
  • Urogenital Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Carcinoma, Ovarian Epithelial
  • Ovarian Diseases
  • Adnexal Diseases
  • Genital Diseases, Female
  • Endocrine System Diseases
  • Gonadal Disorders
  • Carcinoma
  • Bevacizumab
  • Enzyme Inhibitors
  • Antineoplastic Agents
  • Molecular Mechanisms of Pharmacological Action
  • Angiogenesis
  • BRCA1 Mutation
  • BRCA2 Mutation
  • Homologous Recombination Deficiency

Keywords

  • Platinum Refractory/Resistant Recurrent Ovarian Cancer
  • Niraparib
  • Bevacizumab
  • homologous recombination deficiency
  • tumor burden
04

In context

Carcinoma, Ovarian Epithelial Reclassified

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 101 are open to participants now.

This study's planned enrollment of 32 is below the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.

Browse Carcinoma, Ovarian Epithelial studies →

Lead sponsor

Xiaoxiang Chen is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Carcinoma, Ovarian Epithelial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ovarian Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects understand the trial process, sign , agree to participate in the study, and have the ability to follow the protocol;
  2. Participant must be female ≥18 years of age;
  3. confirmed FIGO stage III or IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer;
  4. Participants must have high-grade serous or endometrioid histology;
  5. Subjects were initially treated with platinum, and the disease recurrence occurred within 6 months after the end of the previous platinum-containing chemotherapy, that is, platinum resistance ; Subjects have disease progression during initial platinum based chemotherapy defined as platinum refractory;
  6. Patients may have received a PARP inhibitor as maintenance therapy;
  7. Patients may have received bevacizumab though no other prior use of anti-angiogenic therapy;
  8. Subjects must have (according to RECIST1.1) and radiologically confirmed disease progression at the time of previous treatment; or CA125 elevated for two consecutive times and 2.5 times upper the limit of normal value;
  9. Subject agrees to take blood samples for gBRCA mutations, can provide formalin-fixed, paraffin-embedded tumor tissue samples for sBRCA and homologous recombination deficiency(HRD) detection;
  10. >12 weeks;
  11. Subject's physical status score is 0-2;
  12. Good organ function, including:≥1500/μL;≥100,000/μL;≥10g/dL;Serum creatinine≤1.5 times the value, or ≥60mL/min (calculated according to Cockcroft-Gault formula);Total ≤1.5 times the upper limit of normal value or direct bilirubin≤ 1.0 times the upper limit of normal value; and ALT≤2.5 times the upper limit of normal value. When liver are present, it must be≤5 times the upper limit of normal value;
  13. For women with fertility potential, if blood test or urine pregnancy test is negative within one week before enrollment, effective measures must be taken, such as physical barrier contraceptive method (condom) or complete abstinence. Oral, injectable or implantable hormonal contraceptives are not allowed. Or women without , defined as: I. Natural menopause and menopause for more than 1 year; II. Surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); III. serum follicle-stimulating hormone, luteinizing hormone, and plasma estradiol levels were within the menopausal criteria of the research center laboratory;
  14. Subject is able to adhere to the protocol;
  15. The adverse effect of any previous chemotherapy have recovered to ≤ Grade1 ( v5.0) or baseline levels, except for sensory neuropathy or hair loss with stable symptoms ≤ Grade2 (CTCAE v5.0).

Exclusion criteria

Exclusion Criteria:

  1. Personnel involved in the formulation or implementation of the research plan;
  2. Patient participated in other clinical trails using other experimental drugs at the same time as the study;
  3. People who are known to be allergic to Niraparib or Bevacizumab (or active or inactive ingredients of drugs with similar chemical structure);
  4. People who are inability to swallow oral drugs and any gastrointestinal diseases that may interfere with the absorption and metabolism of the study drugs, such as uncontrollable nausea and vomiting, gastrointestinal obstruction or malabsorption;
  5. Major surgery was performed within 4 weeks before the start of the study or did not recover after the operation;
  6. Received palliative radiotherapy of >20% bone marrow 1 week before enrollment;
  7. The subjects had other malignant diseases in past 2 years, except skin squamous cell carcinoma, basal-like carcinoma, breast intraductal carcinoma in situ, or cervical carcinoma in situ;
  8. Previous or currently diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML);
  9. Patients with serious and uncontrollable diseases or the general situation of the subjects judged by the researchers to be unsuitable for enrolling the study, including but not limited to: active viral infection, such as , , , etc.; severe cardiovascular disease, uncontrollable ventricular arrhythmia, myocardial infarction in the last three months; uncontrollable grand mal epilepsy, Unstable spinal cord compression, superior vena cava syndrome or other mental disorders that affect patients to sign the ; hypertension beyond drug control; immune deficiency (except splenectomy) or other diseases that researchers consider may expose patients to high-risk toxicity;
  10. The previous history of thromboembolism was defined as: uncontrolled pulmonary embolism, deep venous thrombosis, and other related conditions after anticoagulant therapy for more than 3 months before enrollment;
  11. Any medical history or existing clinical evidence indicates that there may be confusion of study results, interference with patients' compliance with the trial protocol throughout the study treatment period, or not in the best interests of patients;
  12. Receive or red blood cell transfusions within 4 weeks;
  13. Patients who are pregnant or lactation, or who plan to become pregnant during study treatment.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Niraparib-bevacizumab combination

    Niraparib-bevacizumab combination therapy until disease progression

    Drug: Niraparib · Drug: Bevacizumab

Interventions

  • Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.

    Also known as: Zejula

  • The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.

    Also known as: Avastin

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as assessed by RECIST1.1.

    Time frame: at 6 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time in months from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death as assessed by RECIST1.1.

    Time frame: Through study completion, an average of 1 year

  2. Disease Control Rate (DCR)

    Disease control rate is defined as the proportion of participants achieving complete response (CR), partial response (PR) or stable disease (SD) according to RECIST1.1.

    Time frame: at 6 months

  3. Duration of Response (DOR)

    DOR is defined as the time from the first date of response until the date of first documented progression.

    Time frame: Through study completion, an average of 1 year

  4. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    To further describe safety and assess toxicities encountered with the use of the proposed treatment regimen in participants.

    Time frame: Through study completion, an average of 1 year

08

Study locations

1 of 1 sites recruiting
  • JiangSu Cancer Hospital
    Nanjing, Jiangsu 210009, China
    Recruiting
09

References and documents

Individual participant data

Plan to share: No — Contact Prof. Chen for primary data.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Mar 2022, 15 months after the start.

Of 51 phase 2 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 92. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 21, 2020
StartActual
Nov 6, 2020
Primary completionEst.
Mar 1, 2022
CompletionEst.
Oct 1, 2022
Last update
Nov 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04556071
Lead sponsor
Xiaoxiang Chen
Responsible party
Xiaoxiang Chen (Academic secretary of gynecological oncology Committee of Jiangsu anti cancer association, Jiangsu Cancer Institute & Hospital) — Sponsor-investigator
First posted
Sep 21, 2020
Start date
Nov 6, 2020
Primary completion
Mar 1, 2022 (estimated)
Completion
Oct 1, 2022 (estimated)
Last update
Nov 10, 2020

Study contacts

Xiaoxiang Chen, MD,PhD
Contact
cxxxxcyd@gmail.com
+86 13851647229
Jing Ni, MD
Contact
nijingwulin@126.com
+86 13327833586
Xiaoxiang Chen, MD,PhD
study chair · Jiangsu Cancer Institute & Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Bevacizumab

Start the discussion